CN101172127A - Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament - Google Patents
Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament Download PDFInfo
- Publication number
- CN101172127A CN101172127A CNA2006101178204A CN200610117820A CN101172127A CN 101172127 A CN101172127 A CN 101172127A CN A2006101178204 A CNA2006101178204 A CN A2006101178204A CN 200610117820 A CN200610117820 A CN 200610117820A CN 101172127 A CN101172127 A CN 101172127A
- Authority
- CN
- China
- Prior art keywords
- folium mori
- extract
- influenza
- mulberry leaf
- leaf extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 240000000249 Morus alba Species 0.000 title claims abstract description 15
- 241000700605 Viruses Species 0.000 title claims description 18
- 239000003814 drug Substances 0.000 title claims description 17
- 208000037797 influenza A Diseases 0.000 title claims description 8
- 235000008708 Morus alba Nutrition 0.000 title abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 18
- 235000004839 Morus alba var multicaulis Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Abstract
The invention discloses mulberry leaf extract, which has the extraction method that ethanol is used for extracting after a mulberry leaf is dried and smashed. The invention also discloses the application of the mulberry leaf extract during the process of preparing the anti influenza A virus. The mulberry leaf extract of the invention has obvious function of anti influenza A virus, and can be applicable for preparing various types of the anti influenza A viruses.
Description
Technical field
The present invention relates to a kind of Folium Mori extract and the application in the preparation anti-influenza A virus medicament thereof.
Background technology
Folium Mori are the leaf of moraceae plants Mulberry (Morus albal.).The history in existing more than 5,000 year of the cultivation of mulberry, its leaf can be brought up silkworm with its abundant nutrition and distinctive composition, bear Bombyx bombycis, reels out silk, and and then has promoted the development of human social economy.Along with the progress of human society, people find that progressively Folium Mori are applied to the mankind, can also treat some disease, further find recent years, and Folium Mori have outstanding health-care effect.Particularly, immeasurable effect is arranged to the reverse of subhealth state.
Cold in nature, the sweet-bitter flavor of Folium Mori product has the function of dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, liver heat removing and eyesight improving, is one of Chinese medicine of using always.Shennong's Herbal claims that Folium Mori are " angle's leaf ", has nourishing YIN and supplementing blood, the liver benefiting ventilation, the effect of antihypertensive diuretic.The Compendium of Material Medica record: Folium Mori are the medicine of brothers Yang Ming, and leaf is fried in shallow oil Dai Ming, can only quench one's thirst, and long hair makes eye bright.The Mulberry Zhibao Dan that protects based on Folium Mori in " Longevity and Life Preservation " " is obeyed not to climb up the longevity certainly " for a long time.Modern pharmacological research proof Folium Mori have a lot of chemical constituents and multiple biological activity.
Influenza virus has first (A), second (B), three kinds of types of third (C) to form, and wherein B-mode very narrow with host range influenza virus C, the extent of injury is also very little.And the extent of injury maximum of influenza A virus, host range is also very extensive, but except that infected person can cause worldwide flu outbreak, also can extensively exist in animal and cause that the animal influenza causes death and die.Present known influenza A virus can infect animals such as tens of kinds of birdss and horse, pig.First type virus belong to orthomyxovirus section (Oythomy Xoviridae) be a class to mucoprotein RNA viruses with special affinity, it is very big to mankind's harm that this for this reason influenza A virus is easy to invade human body upper respiratory tract and pulmonary, intestinal etc.
Though have some synthetic drugs that certain curative effect is also arranged at present, but cause immunity degradation easily and bring other disease the human injury is very big, because this virus is easy to generate variation, also can bring certain difficulty to vaccine work, the Chinese medicine majority is crude drug and part electuary, drug effect has certain slow property, and inconvenience is taken.
Therefore screening is harmless and to have a material of antiviral activity very important and necessary from pure natural plant, our new Wonder research and development centre is existing more than 2 years to the research of Folium Mori, particularly since SARS virus after China takes place, caused that more we have the attention and the sense of responsibility of antiviral natural product to screening.My research and development centre extracts and isolates effect material (being called for short WSHT) from Folium Mori, detect the effect that tangible anti-influenza A virus and bactericidal are arranged through the cell in vitro test.
Summary of the invention
The objective of the invention is to disclose a kind of Folium Mori extract WSHT, and the application in the preparation anti-influenza A virus medicament.
Folium Mori extract WSHT of the present invention, its extracting method is: after Folium Mori drying, the pulverizing, use ethanol extraction.
Among the present invention, what described Folium Mori were preferable is Chinese Morus multicaulis leaf.Morus multicaulis distributes very wide in China, as Shandong, Jiangsu, zhejiang and other places a large amount of plantations are arranged all.
Among the present invention, what described ethanol water concentration was preferable is weight percentage 40%～98%, and what the weight ratio of Folium Mori/ethanol water was preferable is 1: 5～1: 20.
Among the present invention, what described ethanol extraction was preferable is to extract 2 times, and what each time of extracting was preferable is 2 hours, and what the temperature of extraction was preferable is 30 ℃～80 ℃.
In the example of the present invention, for improving the extract activity, after with ethanol extraction, again with macroporous resin on the extract, with the ethanol water eluting of sequence concentration, fraction collection.Preferable being weight percentage of described sequence concentration: 20%, 30%, 50%, 60%, 70%, 80%.
Agents useful for same is all commercially available among the present invention gets.
Another object of the present invention is to disclose the application of Folium Mori extract WSHT of the present invention in the preparation anti-influenza A virus medicament.Described medicine can be forms such as solid, liquid, powder or capsule.
The specific embodiment
Embodiment 1
Folium Mori extract WSHT, its extraction step is as follows:
(1) Chinese Morus multicaulis leaf drying, pulverizing;
(2) with Folium Mori/ratio of 1: 15 of ethanol water weight ratio, the ethanol water with 40% extracts 2 times, and each 2 hours, extracting temperature was 30 ℃;
(3) go up macroporous resin, with 20%, 30%, 50%, 60%, 70%, 80% ethanol water eluting, fraction collection.
Embodiment 2
Folium Mori extract WSHT, its extraction step is as follows:
(1) Chinese Morus multicaulis leaf drying, pulverizing;
(2) with Folium Mori/ratio of 1: 10 of ethanol water weight ratio, the ethanol water with 80% extracts 2 times, and each 2 hours, extracting temperature was 80 ℃;
(3) go up macroporous resin, with 20%, 30%, 50%, 60%, 70%, 80% ethanol water eluting, fraction collection.
Embodiment 3
Folium Mori extract WSHT, its extraction step is as follows:
(1) Chinese Morus multicaulis leaf drying, pulverizing;
(2) with Folium Mori/ratio of 1: 20 of ethanol water weight ratio, the ethanol water with 98% extracts 2 times, and each 2 hours, extracting temperature was 50 ℃;
(3) go up macroporous resin, with 20%, 30%, 50%, 60%, 70%, 80% ethanol elution, fraction collection.
Embodiment 4
Folium Mori extract WSHT, its extraction step is: after the Folium Mori drying and crushing, with Folium Mori/ratio of 1: 5 of ethanol water weight ratio, the ethanol water with 50% extracts 2 times, and each 2 hours, temperature was 50 ℃.
The test of effect embodiment 1 Folium Mori extract WSHT influenza first type virus activity
Test philosophy: with MDCK (Testis et Pentis Canis) cell is virus host, and working sample suppresses virus and causes cytopathy degree (CPE).
Test material:
1. Strain: influenza first type virus (the anti-190-15 of Ji) is cultivated at the chick embryo allantois intracavity and is gone down to posterity (2002.10)-80 ℃ of preservations.
2. sample treatment: sample is dissolved in DMSO, and the reuse culture fluid is made into suitable initial concentration, does 3 times of dilutions with culture fluid, each 8 dilution factor.
3. positive control drug: virazole (RBV) the Zhejiang abundant pharmaceutcal corporation, Ltd of health (lot number 960501).
Method of testing: mdck cell is inoculated 96 well culture plates, puts 5%CO
2, cultivated 24 hours for 37 ℃.Mdck cell adds influenza first type virus 10-4 (100 times of TCID50) respectively, and 37 ℃ of absorption hypsokinesis in 2 hours venom of preventing or cure a disease adds different dilution factor medicines respectively.If virus control and cell contrast were cultivated 36 hours for 37 ℃, observed result, record CPE calculates each sample resisiting influenza virus half-inhibition concentration (IC50).
Test result:
Table 1 Folium Mori extract WSHT anti-influenza A virus active testing result
| Sample concentration | TC5(ug/ml) | IC50(ug/ml) | SI |
| 1/30 times of stock solution | 1200 | 307.2 | 3.87 |
Annotate: TC50 is the poisonous concentration of medicine half in the table; IC50 be medicine to viral half-inhibition concentration, SI is a selection index, SI=TC50/IC50.
Test result:
Be respectively 1200ug/ml and 307.2ug/ml by the poisonous concentration of TC5 medicine half and IC50 virus half-inhibition concentration, SI is that 3.87 data can get: Folium Mori extract WSHT has tangible influenza first type virus activity.
Claims (10)
1. a Folium Mori extract is made by following method: after Folium Mori drying, pulverizing, extract promptly with ethanol water.
2. Folium Mori extract as claimed in claim 1 is characterized in that: described Folium Mori are Chinese Morus multicaulis leaf.
3. Folium Mori extract as claimed in claim 1 is characterized in that: the concentration of described ethanol water is weight percentage 40%～98%.
4. Folium Mori extract as claimed in claim 1 is characterized in that: when ethanol water extracted, the weight ratio of Folium Mori/ethanol water was 1: 5～1: 20.
5. Folium Mori extract as claimed in claim 1 is characterized in that: described ethanol extraction step is for extracting 2 times.
6. Folium Mori extract as claimed in claim 1 is characterized in that: each time of extracting of described ethanol extraction step is 2 hours.
7. Folium Mori extract as claimed in claim 1 is characterized in that: the temperature of described ethanol extraction is 30 ℃～80 ℃.
8. Folium Mori extract as claimed in claim 1 is characterized in that: after the extraction, with macroporous resin on the extract, with the ethanol water eluting of sequence concentration, fraction collection.
9. Folium Mori extract as claimed in claim 8 is characterized in that: described sequence concentration is weight percentage: 20%, 30%, 50%, 60%, 70%, 80%.
10. the application of Folium Mori extract as claimed in claim 1 in the preparation anti-influenza A virus medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101178204A CN101172127B (en) | 2006-10-31 | 2006-10-31 | Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101178204A CN101172127B (en) | 2006-10-31 | 2006-10-31 | Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101172127A true CN101172127A (en) | 2008-05-07 |
| CN101172127B CN101172127B (en) | 2011-12-07 |
Family
ID=39421015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101178204A Expired - Fee Related CN101172127B (en) | 2006-10-31 | 2006-10-31 | Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101172127B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110065752A1 (en) * | 2009-09-04 | 2011-03-17 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
-
2006
- 2006-10-31 CN CN2006101178204A patent/CN101172127B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110065752A1 (en) * | 2009-09-04 | 2011-03-17 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
| US20160243096A1 (en) * | 2009-09-04 | 2016-08-25 | Emergent Virology Llc | Methods of treating orthomyxoviral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101172127B (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101804162B (en) | Anti-newcastle disease virus Chinese medicinal composition and preparation method thereof | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| CN102988469A (en) | Traditional Chinese medicine composition for preventing and treating influenza virus infection as well as preparation method and application thereof | |
| CN101259160B (en) | Compound preparations for treating birdsvirosis and preparation thereof | |
| CN101172127B (en) | Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament | |
| CN107279572A (en) | A kind of Chinese herbal feed additive for preventing and treating animal viral disease | |
| CN103636968A (en) | Anti-avian influenza feed additive | |
| CN107661416A (en) | A kind of traditional Chinese medicine extraction compound pharmaceutical for preventing and treating livestock and birds respiratory disease | |
| CN104585511B (en) | Prevent the feed addictive of birds influenza pestilence | |
| CN102670694A (en) | Traditional Chinese medicine combination for treating porcine pseudorabies and preparation method and application thereof | |
| CN105395644A (en) | Traditional Chinese medicinal composition for preventing and treating coccidiosis in chicken as well as preparation method and application of traditional Chinese medicinal composition | |
| CN100431564C (en) | Chinese medicine composition for preventing avian flu | |
| CN103070993A (en) | Traditional Chinese medicine composition for treating respiratory disease of livestock and poultry and feed of traditional Chinese medicine composition | |
| CN104758340B (en) | Coffee mesitoyl quinine acid extract and its preparation method and application in a kind of folium lonicerae | |
| CN105497291A (en) | Medicine composition for treating schizophrenia | |
| CN101314033A (en) | Oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof | |
| CN104306441A (en) | Traditional Chinese medicine oral solution for treating swine influenza and preparation method thereof | |
| CN103860947A (en) | Medicinal preparation for treating alopecia totalis and alopecia universalis | |
| CN105168817B (en) | A kind of Chinese medicine composition for preventing Duckling flavivirus disease | |
| CN102078529B (en) | Chinese medicinal preparation for treating common cold in children | |
| CN108261483A (en) | It is a kind of to be used to treat Rhizoma Belamcandae oral liquid of chicken necrotizing enterocolitis and preparation method thereof | |
| CN108524746A (en) | A kind of Chinese medicine composition of prevention fowl cough | |
| CN102657768A (en) | Chinese medicinal granules for preventing and treating chicken coccidiosis | |
| CN104116029B (en) | For the health food and preparation method thereof of develop immunitypty | |
| CN107320671B (en) | Insecticidal traditional Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080507 Assignee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Assignor: SHANGHAI WENDA BIOTECH Inc. Contract record no.: X2020980002915 Denomination of invention: Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament Granted publication date: 20111207 License type: Exclusive License Record date: 20200609 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mulberry leaf extract and application of mulberry leaf extract in preparing anti-influenza A virus medicament Effective date of registration: 20200609 Granted publication date: 20111207 Pledgee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Pledgor: SHANGHAI WENDA BIOTECH Inc. Registration number: Y2020980002917 |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Assignor: SHANGHAI WENDA BIOTECH Inc. Contract record no.: X2020980002915 Date of cancellation: 20210809 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210809 Granted publication date: 20111207 Pledgee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Pledgor: SHANGHAI WENDA BIOTECH Inc. Registration number: Y2020980002917 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20211031 |